ChinaAMC Hang Seng Biotech ETF (03069.HK) Falls 2.10% Intraday as Healthcare Stocks Buck a Firmer Market

NewTimeSpace News: As of 10:06 on November 2, the ChinaAMC Hang Seng Biotech ETF (03069.HK) fell 2.10% to a latest price of HK$13.980. The ETF has traded 3.8503 million units so far today for a turnover of HK$53.8602 million at an average price of HK$13.989, with a turnover rate of 2.12%. It is down 2.10% so far this week. Its current net asset value per unit is HK$14.1609, and its assets under management stand at HK$2.569 billion.

(Note on scope: the net asset value per unit and assets under management are as of October 30, 2026; the week-to-date change is measured against the closing price of HK$14.280 on October 30.)

On the news front, Hong Kong stocks broadly advanced in early trade on November 2, with the Hang Seng Index up 0.80% at 23,480.05 and the Hang Seng TECH Index up 0.98% at 3,791.52, while healthcare ran counter to the trend—the pharmaceutical and biotech contract services sector fell 3.24% and the biotechnology sector 2.00%. Among key constituents, WuXi Biologics fell 1.21% to HK$43.94 after touching HK$42.72 intraday, and Akeso dropped 1.53% to HK$80.25 after a low of HK$79.10. In the prior session on October 30, the three main Hong Kong indices all closed higher, with the Hang Seng Index up 1.46% at 23,294.42 and the Hang Seng TECH Index up 0.29% at 3,754.90; for the month, the Hang Seng Index fell 5.36% and the Hang Seng TECH Index 11.73%.

The ChinaAMC Hang Seng Biotech ETF (03069.HK) is a passively managed exchange-traded fund under China Asset Management (Hong Kong), with the investment objective of closely tracking the performance of the Hang Seng Biotech Index. Compiled by Hang Seng Indexes Company on a net total return basis, the index reflects the overall performance of the 30 largest biotech companies listed in Hong Kong that are eligible for Southbound trading, including pre-revenue companies listed under Chapter 18A of the Listing Rules; its constituents span the Hang Seng Industry Classification System sub-sectors of biotechnology, pharmaceuticals, pharmaceutical distribution, pharmaceutical and biotech contract services, and medical devices and supplies, weighted by freefloat-adjusted market capitalisation with a 10% cap on any single constituent.

Sinolink Securities believes the pharmaceutical supply chain's third-quarter 2026 results continue to validate a high-growth cycle: CDMO revenue growth accelerated to 28% from 26% at the interim stage, CRO revenue returned to growth at 16% year on year versus 13% at the interim, and the life sciences upstream segment lifted revenue growth to 25% with non-recurring net profit growth of 55%. WuXi AppTec has raised its guidance for two consecutive quarters, reflecting both continued onshore and offshore order wins by downstream innovative drug developers and a firmer upcycle in CXO. The brokerage judges the industry has entered a new recovery upcycle marked by the resonance of domestic and external demand, volume growth in new modalities, and sequential improvement in orders and earnings.